本文選題：血管畸形 + 介入治療��； 參考：《中國協(xié)和醫(yī)科大學(xué)》2007年碩士論文

【摘要】： 【背景】頭頸部血管畸形和／或血管瘤是小兒最常見的良性腫瘤之一，發(fā)病率為2.5-12.0％，約占所有軟組織腫瘤的7％，全身血管瘤60％。 頭頸部血管畸形具有下列臨床特點：1．部位表淺，臨床癥狀發(fā)現(xiàn)早；2．病變嚴重程度與病程持續(xù)時間明顯相關(guān)，應(yīng)采取手段及早中斷病程；3．治療效果后的面貌外觀對患者非常重要，要求創(chuàng)傷小，代價小。 頭頸部血管畸形的特點，決定了栓塞技術(shù)理應(yīng)成為治療血管畸形最好的方法，而目前的栓塞介入在頭頸部血管畸形的治療上處于被動或輔助地位，很大程度上與目前應(yīng)用的各種栓塞劑的弊端有關(guān)，因此，只有栓塞劑的創(chuàng)新和變革，，才能使介入栓塞治療在頭頸部血管畸形的治療中處于主動(沒有明顯癥狀時就給于干預(yù)治療)和主導(dǎo)地位(充分發(fā)揮其創(chuàng)傷小的特點)。本課題組受到“動脈粥樣硬化病變始于內(nèi)皮損傷和成纖維細胞增生”這一假說的啟發(fā)，提出了含自體成纖維細胞的生物栓塞劑在頭頸部血管畸形介入治療中的應(yīng)用研究設(shè)想。 【實驗?zāi)康摹刻剿魅∽云つw組織的自體成纖維細胞體外培養(yǎng)、標記的方法以及血管內(nèi)注射后的成活性，為應(yīng)用含自體成纖維細胞的液體栓塞劑介入治療頭頸部血管畸形提供實驗依據(jù)。 【實驗方法】取自SD大鼠的真皮組織通過組織貼塊法體外培養(yǎng)原代成纖維細胞，在細胞傳至第5代時，對細胞進行特殊標記(Brdu標記)后注射入大鼠血管內(nèi)，一定時間后，通過血管切片、染色(Brdu，ki67，波形蛋白染色)，了解成纖維細胞的成活性和功能狀態(tài)。 【實驗結(jié)果】組織貼塊法體外培養(yǎng)原代成纖維細胞獲得成功。血管切片、染色的結(jié)果證明，注射入血管內(nèi)的成纖維細胞成活良好，分裂、增殖活躍，在注射后第5周血管腔幾乎被成纖維細胞分泌的纖維組織封閉。 【結(jié)論】含自體成纖維細胞的液體栓塞劑介入治療血管畸形是可行的。
[Abstract]:[background] head and neck vascular malformation and / or hemangioma is one of the most common benign tumors in children. The incidence is 2.5-12.0, accounting for about 7 of all soft tissue tumors and 60 percent of systemic hemangioma. The head and neck vascular malformations have the following clinical features: 1. Superficial site, clinical symptoms found early 2. The severity of the disease was significantly correlated with the duration of the disease, and should be interrupted as early as possible. The appearance after treatment is very important for patients, requiring less trauma and less cost. The characteristics of head and neck vascular malformation determine that embolization should be the best way to treat vascular malformation, and the current embolization intervention is in a passive or auxiliary position in the treatment of head and neck vascular malformation. This is largely due to the drawbacks of the various embolic agents currently being used, so only the innovations and changes in the embolism, In order to make the interventional embolization in the treatment of head and neck vascular malformation in the initiative (no obvious symptoms are given to the intervention) and the dominant position (give full play to its small trauma characteristics). Inspired by the hypothesis that atherosclerotic lesions begin with endothelial injury and fibroblast proliferation, our research group proposed the application of biomembolic agents containing autologous fibroblasts in the interventional treatment of vascular malformations in the head and neck. [objective] to explore the in vitro culture, labeling and intravascular injection of autologous fibroblasts from skin tissue. To provide experimental evidence for interventional treatment of vascular malformation of head and neck with liquid embolic agent containing autologous fibroblasts. [methods] the primary fibroblasts were cultured in vitro from the dermal tissue of SD rats by tissue patch method. When the cells were transferred to the fifth passage, the cells were labeled with Brdu) and then injected into the blood vessels of the rats. After a certain time, the fibroblasts were injected into the blood vessels of the rats. The activity and function of fibroblasts were studied by means of vascular sections, Brduduki 67 and vimentin staining. The primary fibroblasts were successfully cultured in vitro by tissue patch method. The results showed that the fibroblasts injected into the blood vessels survived well, divided and proliferated actively. At the 5th week after injection, the vascular lumen was almost blocked by the fibrous tissue secreted by the fibroblasts. Conclusion it is feasible to treat vascular malformation with liquid embolic agent containing autologous fibroblasts.
【學(xué)位授予單位】：中國協(xié)和醫(yī)科大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2007
【分類號】：R329

【參考文獻】

相關(guān)期刊論文 前1條

1 蔡煦;血管重構(gòu)、血管外膜與冠狀動脈介入后再狹窄的關(guān)系[J];國外醫(yī)學(xué)(內(nèi)科學(xué)分冊);1999年02期

本文編號：1869969